HU

Humana IncNYSE HUM Stock Report

Last reporting period 30 Sep, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

37.593

Large

Exchange

XNYS - New York Stock Exchange, Inc

HUM Stock Analysis

HU

Avoid

Based on Eyestock quantitative analysis, HUM`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-16/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-22.2 %

Greatly overvalued

Market cap $B

37.593

Dividend yield

1.11 %

Shares outstanding

124.97 B

Humana Inc. is a health and well-being company. The Company operates through two segments: Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly through group Medicare accounts. It also includes its contract with the Centers for Medicare and Medicaid Services (CMS) to administer the Limited Income Newly Eligible Transition (LI-NET), prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. The Insurance segment also includes products consisting of employer group commercial fully-insured medical and specialty health. The CenterWell segment represents its payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The Company’s subsidiaries include Mid-South Home Health Agency, LLC, Premier Home Health Agency, LLC and Humana Regional Health Plan, Inc.

View Section: Eyestock Rating